28. 全身性アミロイドーシス Systemic amyloidosis Clinical trials / Disease details
臨床試験数 : 261 / 薬物数 : 276 - (DrugBank : 81) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 178
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2006-001066-16-GB (EUCTR) | 25/08/2010 | 18/06/2010 | A randomized, double-blind, placebo-controlled, international multi-center trial ofdiflunisal on neurologic disease progression in 200 familial amyloid subjects - The effect of diflunisal on familial amyloidosis | A randomized, double-blind, placebo-controlled, international multi-center trial ofdiflunisal on neurologic disease progression in 200 familial amyloid subjects - The effect of diflunisal on familial amyloidosis | Hereditary neuropathic amyloidosis MedDRA version: 11.;Level: LLT;Classification code 10019889;Term: Hereditary neuropathic amyloidosis | Trade Name: Dolobid Product Name: diflunisal (dolobid) INN or Proposed INN: diflunisal Other descriptive name: 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid | John L. Berk | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 140 | United Kingdom;Italy;Sweden | |||
| 2 | EUCTR2006-001066-16-SE (EUCTR) | 04/01/2007 | 09/11/2006 | The effect of diflunisal (IND 68092) on familial amyloidosis - The Diflunisal Trial | The effect of diflunisal (IND 68092) on familial amyloidosis - The Diflunisal Trial | Familial Amyloid Polyneuropathy (FAP) | Trade Name: Dolobid Product Name: diflunisal (dolobid) INN or Proposed INN: diflunisal Other descriptive name: 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid | John L. Berk, M.D. | NULL | Not Recruiting | Female: yes Male: yes | 200 | United Kingdom;Italy;Sweden |